
News|Articles|March 1, 2005
Ziprasidone and risperidone equally efficacious for treatment of acute exacerbation of schizophrenia or schizoaffective disorder
Ziprasidone (Geodon, Pfizer) and risperidone (Risperdal, Janssen) are equally efficacious in the treatment of patients with acute exacerbation of schizophrenia and schizoaffective disorder, with ziprasidone demonstrating a lower movement disorder burden and less effect on prolactin concentrations and weight than risperidone.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
AI Helps Managed Care Identify High-Risk Patients Sooner and More Precisely | AMCP Nexus 2025
2
Real-World Study Shows $330,000 Cost Difference Between CAR T and BiTE Therapies | AMCP Nexus 2025
3
Cardiovascular, Renal and Metabolic Conditions Increasingly Prevalent, Expensive in Medicare Fee-For-Service Population | AMCP Nexus 2025
4
Real-World Data Drives CAR T Treatment Decisions, Reveals Benefits of Earlier Administration | AMCP Nexus 2025
5



















































